Dr Falk Pharma acquires spinout Kynos Therapeutics

German drugmaker Dr Falk Pharma GmbH today   announced completion of the acquisition of Kynos Therapeutics, a clinical   stage biopharmaceutical company focusing on the development of novel KMO   inhibitors for acute and chronic inflammatory diseases. Financial terms of   the transaction are not disclosed.

The company was spun out of the University of   Edinburgh by co-founders Professors Damian Mole and Scott Webster, together   with founding investor Epidarex Capital, a leading early-stage transatlantic   venture fund. The company has been backed by investment from Epidarex   Capital, IP Group, and Scottish Enterprise and led by CEO Jonathan Savidge   since 2022.

Since its foundation, Kynos Therapeutics has   progressed development of its lead molecule, KNS366, a highly potent and   selective first-in-class inhibitor of the enzyme kynurenine 3-monooxygenase   (KMO), through a Phase I trial. KNS366 was shown to be safe and   well-tolerated and led to a dose-dependent inhibition of the enzyme KMO and   modulation of its downstream metabolites.